Skip to main content
Equibles
VRTX logo

VRTX · Vertex Pharmaceuticals Inc / Ma

Track VRTX — free

Use VRTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$546.12 -11.84 (-2.12%) At close · Sep 4
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$141.42B
Shares
253.46M

VRTX metrics

80 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$546.12
Market cap
$141.42B

Price action

19 metrics
Price change (1W)
+1.9%
Price change (30D)
+15.3%
Price change (3M)
+26.3%
Price change (6M)
+21.1%
Price change (YTD)
+23.1%
Price change (1Y)
+40.7%
Trailing year
Price change (5Y)
+181.7%
52-week high
$557.96
52-week low
$376.62
Change from 52-week high
+0.0%
Change from 52-week low
+48.1%
Annualized volatility
28.5%
Beta
0.5
RSI (14D)
67.5
Price vs SMA 50
+10.0%
Price vs SMA 200
+19.8%
Avg volume (3M)
1.49M
Relative volume
0.5
Average dollar volume
$734.13M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
253.46M

Valuation

12 metrics
P / E (TTM)
32.5
Trailing earnings · reciprocal yield 3.1%
PEG ratio
4.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.2×
reciprocal yield 8.9%
P / book
7.0
reciprocal yield 14.3%
FCF yield
2.7%
TTM · current market cap
Buyback yield
1.4%
P / FCF
37.3
reciprocal yield 2.7%
P / operating cash flow
32.9
reciprocal yield 3.0%
Earnings yield
3.1%

Historical valuation

8 metrics
P / E historical average (3Y)
28.4×
reciprocal yield 3.5%
P / E historical average (5Y)
26.9×
reciprocal yield 3.7%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
86.0%
Operating margin
38.0%
Trailing 12 months
Net margin
35.0%
Gross profit (TTM)
—
Operating profit (TTM)
$4.78B
Net income (TTM)
$4.41B
Trailing 12 months
Diluted EPS (TTM)
$17.17
FCF margin
30.2%
Effective tax rate
16.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.48

Growth

11 metrics
Revenue growth YoY
+12.5%
Year over year
Net income growth YoY
+6.5%
Revenue (TTM)
$12.59B
Trailing 12 months
EPS growth YoY
+8.0%
Shares change YoY
-1.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.4%
Revenue CAGR (5Y)
+14.1%
EPS CAGR (3Y)
+6.1%
EPS CAGR (5Y)
+8.3%
FCF CAGR (3Y)
-6.6%
FCF CAGR (5Y)
+1.3%

Quality

14 metrics
Return on equity
21.8%
Return on assets
16.1%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
$5.00B
Free cash flow (TTM)
$3.80B
Quick ratio
2.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.14B
Total assets
$27.42B
Total debt
$105.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.29B
Capital expenditures (TTM)
$496.80M
R&D (TTM)
$3.91B
SG&A (TTM)
$2.01B
Stock compensation (TTM)
$689.10M
R&D / revenue
31.0%
Stock compensation / revenue
5.5%

Ownership (13F)

3 metrics
13F filers
1,753
13F filer change QoQ
+47
Institutional ownership
96.3%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.59M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 875320 CUSIP 92532F100 13F (30d) 929 filings 883 filers Visit website Investor relations